Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Inclusion Criteria

• •1. Patient is ≥18 years of age
• •2. Written Informed Consent provided by patient
• •3. Diagnosis of any kind of carcinoma
• •4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
• •5. Proceeding onto therapy for treatment
• •6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)